Bristol-Myers Squibb Abilify long-term use
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Bristol-Myers Squibb/Otsuka's Abilify (aripiprazole) Aug. 28 for maintaining stability in patients with schizophrenia. The sNDA was based on a 310-patient placebo-controlled trial in which patients who were stable on other antipsychotics were switched to Abilify and treated for up to 26 weeks. Abilify patients "experienced a significantly longer time to relapse over the subsequent 26 weeks compared to those receiving placebo," labeling states. The relative risk of relapse for Abilify patients was half that of placebo patients, according to the firms. The companies also reported that "there were no medically important differences between Abilify and placebo in several metabolic measures." Overall mean weight change was 1.3 kg for Abilify compared to -0.9 kg for placebo. Bristol/Otsuka submitted an sNDA for treatment of acute mania June 25 (1Pharmaceutical Approvals Monthly Aug. 1, 2003, In Brief)...
You may also be interested in...
Abilify for bipolar mania
Bristol/Otsuka's June 25 Abilify (aripiprazole) submission for treatment of acute bipolar mania is first sought labeling expansion for the atypical antipsychotic. The indication was included in the initial NDA, but Bristol withdrew it after one of two pivotal trials failed to meet the primary endpoint (1Pharmaceutical Approvals Monthly May 1, 2003, p. 27). The sNDA includes three, three-week placebo-controlled studies and one 12-week study comparing Abilify to haloperidol. Abilify did not reach statistical significance in one of the three-week studies; the sponsors attributed the finding to "a high placebo response rate (approximately 40%)." In the other studies, aripiprazole was superior to placebo and comparable to haloperidol. Among the atypicals, acute bipolar mania indications are held by Lilly's Zyprexa (ziprasidone) and pending for AstraZeneca's Seroquel (quetiapine) and J&J's Risperdal (risperidone)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.